Gumuslu S - Search Results

1

Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up.

Yalcin AD, Uçar S, Gumuslu S, Strauss LG. Yalcin AD, et al. Among authors: gumuslu s. Immunopharmacol Immunotoxicol. 2013 Aug;35(4):524-7. doi: 10.3109/08923973.2013.811598. Epub 2013 Jul 10. Immunopharmacol Immunotoxicol. 2013. PMID: 23841472 Clinical Trial.

2

Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment.

Yalcin AD, Gorczynski RM, Parlak GE, Kargi A, Bisgin A, Sahin E, Kose S, Gumuslu S. Yalcin AD, et al. Among authors: gumuslu s. Clin Lab. 2012;58(1-2):89-96. Clin Lab. 2012. PMID: 22372350

3

Systemic levels of ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis.

Yalcin AD, Gumuslu S, Parlak GE, Bisgin A, Yildiz M, Kargi A, Gorczynski RM. Yalcin AD, et al. Among authors: gumuslu s. Immunopharmacol Immunotoxicol. 2012 Dec;34(6):1047-53. doi: 10.3109/08923973.2012.697902. Epub 2012 Jun 28. Immunopharmacol Immunotoxicol. 2012. PMID: 22737977 Clinical Trial.

4

D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment.

Yalcin AD, Celik B, Gumuslu S. Yalcin AD, et al. Among authors: gumuslu s. Expert Opin Biol Ther. 2014 Mar;14(3):283-6. doi: 10.1517/14712598.2014.875525. Epub 2013 Dec 23. Expert Opin Biol Ther. 2014. PMID: 24359555

5

Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis.

Yalcin AD, Gumuslu S, Parlak GE, Bısgın A. Yalcin AD, et al. Among authors: gumuslu s. Med Sci Monit. 2012 Oct;18(10):CR617-21. doi: 10.12659/msm.883488. Med Sci Monit. 2012. PMID: 23018355 Free PMC article. Clinical Trial.

6

There might be a role for CD200 in the pathogenesis of autoimmune and inflammatory skin disorders.

Akman-Karakaş A, Yalcin AD, Koç S, Gumuslu S, Senol YY, Özkesici B, Genc GE, Ergun E, Ongut G, Yilmaz E, Uzun S, Alpsoy E. Akman-Karakaş A, et al. Among authors: gumuslu s. Med Sci Monit. 2013 Oct 25;19:888-91. doi: 10.12659/MSM.889624. Med Sci Monit. 2013. PMID: 24157657 Free PMC article.

7

Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200.

Yalcin AD, Genc GE, Celik B, Gumuslu S. Yalcin AD, et al. Among authors: gumuslu s. Clin Lab. 2014;60(3):523-4. doi: 10.7754/clin.lab.2013.130642. Clin Lab. 2014. PMID: 24697134

8

Evaluation of soluble CD200 levels in type 2 diabetic foot and nephropathic patients: association with disease activity.

Arik HO, Yalcin AD, Celik B, Seyman D, Tetik G, Gursoy B, Kose S, Gumuslu S. Arik HO, et al. Among authors: gumuslu s. Med Sci Monit. 2014 Jun 26;20:1078-81. doi: 10.12659/MSM.890517. Med Sci Monit. 2014. PMID: 24964809 Free PMC article.

9

Evaluation of d-dimer, CXCL8, homocysteine, eosinophil cationic peptide, 25(OH)-vitamin D and immunomodulatory OX-2 levels in allergic patients.

Tural Onur S, Yalcin AD, Celik B, Gumuslu S. Tural Onur S, et al. Among authors: gumuslu s. J Asthma. 2015 Mar;52(2):123-7. doi: 10.3109/02770903.2014.936450. Epub 2015 Jan 13. J Asthma. 2015. PMID: 24986253

10

CXCL8, IL-1β and sCD200 are pro-inflammatory cytokines and their levels increase in the circulation of breast carcinoma patients.

Celik B, Yalcin AD, Genc GE, Bulut T, Kuloglu Genc S, Gumuslu S. Celik B, et al. Among authors: gumuslu s. Biomed Rep. 2016 Aug;5(2):259-263. doi: 10.3892/br.2016.709. Epub 2016 Jun 30. Biomed Rep. 2016. PMID: 27446554 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

99 results

Search Page

Filters